ロード中...
Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca
BACKGROUND: OTX-101 is approved for treatment of keratoconjunctivitis sicca (KCS). We present results of a phase 3 worse-eye efficacy analysis and 1-year safety extension. METHODS: During the double-masked treatment phase, patients with bilateral KCS were randomized 1:1 to 12 weeks OTX-101 or vehicl...
保存先:
| 出版年: | Clin Ophthalmol |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7811471/ https://ncbi.nlm.nih.gov/pubmed/33469259 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OPTH.S279364 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|